ERBB2 G292R

CI-VAR-00001698Explore in graph →NP_004439.2:p.Gly292ArgNM_004448.4:c.874G>CCIViC 4663

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gallbladder Carcinoma1
ERBB2 G292R	(oncogenic)	Oncogenic	D	Supports Oncogenicity	2	submitted	EID12117 The ERBB2 G292R variant was observed in 1/57 normal/tumor pairs of human gallbladder carcinoma profiled by next-generation sequencing. Human gallbladder cancer cell lines (GBC-SD and NOZ) were transie… (full text at CIViC) PMID 24997986 · Li et al., 2014 · Open in CIViC	civic
Malignant Bladder Neoplasm1
ERBB2 G292R	Neratinib	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID12119 In the SUMMIT basket trial (clinicaltrials.gov identifier NCT01953926) patients with solid tumors of various histologies harboring mutations of either HER2 or HER3 were enrolled and treated with the p… (full text at CIViC) PMID 29420467 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm1
ERBB2 G292R	Afatinib + Lapatinib + Neratinib + Osimertinib + TrastuzumabSubstitutes	Predictive	D	Supports Sensitivity Response	3	submitted	EID12116 A sequencing-based method was used to assess the sensitivity of this variant relative to wild-type to trastuzumab, lapatinib, sapatinib, afatinib, neratinib and osimertinib. Results indicated sensitiv… (full text at CIViC) PMID 29967253 · Nagano et al., 2018 · Open in CIViC	civic

Unmapped disease1unmapped disease
ERBB2 G292R	(functional)	Functional	D	Supports Gain Of Function	2	submitted	EID12118 A computational prediction algorithm based on genomic and proteomic features deemed critical for oncogenicity was applied to the sequences of 820 mutations within the project GENIE dataset; this algor… (full text at CIViC) PMID 35503682 · Ishiyama et al., 2023 · Open in CIViC	civic